ATE397457T1 - Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen - Google Patents
Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffenInfo
- Publication number
- ATE397457T1 ATE397457T1 AT99965991T AT99965991T ATE397457T1 AT E397457 T1 ATE397457 T1 AT E397457T1 AT 99965991 T AT99965991 T AT 99965991T AT 99965991 T AT99965991 T AT 99965991T AT E397457 T1 ATE397457 T1 AT E397457T1
- Authority
- AT
- Austria
- Prior art keywords
- ctla
- stimulation
- antigens
- against self
- cells against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11076198P | 1998-12-03 | 1998-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE397457T1 true ATE397457T1 (de) | 2008-06-15 |
Family
ID=22334796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99965991T ATE397457T1 (de) | 1998-12-03 | 1999-12-03 | Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1137436B1 (de) |
JP (1) | JP5341287B2 (de) |
AT (1) | ATE397457T1 (de) |
AU (1) | AU774962B2 (de) |
CA (1) | CA2352783C (de) |
CY (1) | CY1108318T1 (de) |
DE (1) | DE69938871D1 (de) |
DK (1) | DK1137436T3 (de) |
ES (1) | ES2308857T3 (de) |
PT (1) | PT1137436E (de) |
WO (1) | WO2000032231A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
KR100942863B1 (ko) * | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
WO2002000692A2 (en) * | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: pd-1 ligands and uses therefor |
DE10161767T1 (de) | 2002-07-03 | 2018-06-07 | Honjo Tasuku | Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten |
CN1240436C (zh) * | 2002-08-28 | 2006-02-08 | 上海益众生物技术有限公司 | 成骨生长肽与粒细胞集落刺激因子在造血方面的协同作用 |
WO2004081021A2 (en) * | 2003-03-12 | 2004-09-23 | Duke University | Oligonucleotide mimetics |
US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
US7494779B2 (en) | 2004-06-14 | 2009-02-24 | Li-Te Chin | Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist |
AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
WO2006124667A2 (en) | 2005-05-12 | 2006-11-23 | Zymogenetics, Inc. | Compositions and methods for modulating immune responses |
SI1907000T2 (sl) | 2005-06-08 | 2020-07-31 | Dana-Farber Cancer Institute | Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies programmed for death ligand 1 (PD-L1) |
CA2630157C (en) | 2005-12-07 | 2018-01-09 | Medarex, Inc. | Ctla-4 antibody dosage escalation regimens |
AU2009319701B2 (en) | 2008-11-28 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods for the treatment of infections and tumors |
US8709417B2 (en) | 2009-09-30 | 2014-04-29 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
AU2010308030B2 (en) | 2009-10-12 | 2014-05-29 | Pfizer Inc. | Cancer treatment |
MX359257B (es) * | 2012-05-04 | 2018-09-19 | Pfizer | Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna. |
WO2013169971A1 (en) | 2012-05-10 | 2013-11-14 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
EP3757130A1 (de) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Verfahren zur behandlung von blutkrebs |
CN111167008A (zh) | 2013-12-05 | 2020-05-19 | 免疫系统公司 | 利用射频电学膜击穿(rf-emb)的癌症免疫疗法 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
US11344620B2 (en) | 2014-09-13 | 2022-05-31 | Novartis Ag | Combination therapies |
PL3240801T3 (pl) | 2014-12-31 | 2021-06-14 | Checkmate Pharmaceuticals, Inc. | Skojarzona immunoterapia nowotworów |
CN114907481A (zh) | 2015-03-23 | 2022-08-16 | 震动疗法股份有限公司 | Icos的抗体 |
PL3303394T3 (pl) | 2015-05-29 | 2020-11-16 | Agenus Inc. | Przeciwciała anty-ctla-4 i sposoby ich zastosowania |
CN108350505A (zh) | 2015-10-22 | 2018-07-31 | 震动疗法股份有限公司 | 用于测定icos表达的基因标志 |
US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
CN109069624A (zh) * | 2016-01-15 | 2018-12-21 | 瑞美控股有限责任公司 | 癌症的免疫治疗 |
JP6992068B2 (ja) | 2016-12-07 | 2022-02-03 | アジェナス インコーポレイテッド | 抗ctla-4抗体およびそれらの使用方法 |
MX2019009660A (es) | 2017-02-28 | 2019-10-02 | Bristol Myers Squibb Co | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. |
KR20210010862A (ko) | 2018-04-18 | 2021-01-28 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 |
TW202011984A (zh) | 2018-04-18 | 2020-04-01 | 美商山可爾股份有限公司 | IL-15/IL-15Rα異二聚體Fc融合蛋白及其用途 |
US20210236694A1 (en) * | 2018-05-03 | 2021-08-05 | The Johns Hopkins University | Induction of anti-tumoral immune microenvironments |
JP2022503959A (ja) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | Il-12ヘテロ二量体fc-融合タンパク質 |
WO2020077276A2 (en) | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
AU2020358979A1 (en) | 2019-10-03 | 2022-04-21 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
JP7405361B2 (ja) | 2019-10-21 | 2023-12-26 | 東亞合成株式会社 | 抗腫瘍ペプチドおよびその利用 |
JP2021120355A (ja) | 2020-01-30 | 2021-08-19 | 東亞合成株式会社 | Ctla4とb7タンパク質との結合を抑制するペプチドおよびその利用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL92382A (en) * | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
WO1998042752A1 (en) * | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
KR100942863B1 (ko) * | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
-
1999
- 1999-12-03 AU AU21649/00A patent/AU774962B2/en not_active Expired
- 1999-12-03 JP JP2000584920A patent/JP5341287B2/ja not_active Expired - Lifetime
- 1999-12-03 CA CA2352783A patent/CA2352783C/en not_active Expired - Lifetime
- 1999-12-03 ES ES99965991T patent/ES2308857T3/es not_active Expired - Lifetime
- 1999-12-03 WO PCT/US1999/028739 patent/WO2000032231A1/en active IP Right Grant
- 1999-12-03 PT PT99965991T patent/PT1137436E/pt unknown
- 1999-12-03 EP EP99965991A patent/EP1137436B1/de not_active Expired - Lifetime
- 1999-12-03 AT AT99965991T patent/ATE397457T1/de active
- 1999-12-03 DK DK99965991T patent/DK1137436T3/da active
- 1999-12-03 DE DE69938871T patent/DE69938871D1/de not_active Expired - Lifetime
-
2008
- 2008-09-04 CY CY20081100953T patent/CY1108318T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2308857T3 (es) | 2008-12-01 |
AU2164900A (en) | 2000-06-19 |
PT1137436E (pt) | 2008-09-15 |
JP5341287B2 (ja) | 2013-11-13 |
EP1137436A1 (de) | 2001-10-04 |
WO2000032231A1 (en) | 2000-06-08 |
AU774962B2 (en) | 2004-07-15 |
DK1137436T3 (da) | 2008-10-13 |
CA2352783A1 (en) | 2000-06-08 |
CY1108318T1 (el) | 2014-02-12 |
DE69938871D1 (de) | 2008-07-17 |
CA2352783C (en) | 2012-04-10 |
EP1137436B1 (de) | 2008-06-04 |
JP2002531416A (ja) | 2002-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE397457T1 (de) | Stimulierung von t-zellen gegen selbstantigene unter verwendung von ctla-4 inhibierenden wirkstoffen | |
ES2163034T3 (es) | Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana. | |
SE9700182D0 (sv) | Implantable heart stimulator | |
ATE552849T1 (de) | Behandlungsverfahren unter verwendung von ctla-4 antikörpern | |
FR12C0004I2 (fr) | Anticorps contre l'antigene ctla-4 humain et utilisation | |
BR0113491A (pt) | Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente. | |
ATE324119T1 (de) | Verwendung von saccharid-konjugaten | |
EP1025856A3 (de) | Verfahren zur Modulation von T-Zell Unempfänglichkeit | |
CY1106046T1 (el) | Μεθοδος για την θεραπευτικη αγωγη ινωσεως με χρησιμοποιηση ενος ανταγωνιστου της αλφα-4-υπομοναδος της ιντεγκρινης | |
NO971341D0 (no) | Promoter for reseptor tyrosinkinase TIE | |
ATE239474T1 (de) | Verwendung von levobupivacain | |
DK0952772T3 (da) | Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration | |
TR200102034T2 (tr) | Anti kanser aşılaması için antikorların kullanılması | |
EA200100264A1 (ru) | Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly | |
DK0768886T3 (da) | Endothelforingseffekter og behandling af vasospastiske lidelser | |
ES2154290T3 (es) | Estimulacion de la diferenciacion celular por sindecano. | |
EE9800315A (et) | Meetod südamepuudulikkuse käitlemiseks endoteliini antagonistide abil | |
NO20060637L (no) | Autologe selv-toleranse induserende celler av monocytisk opprinnelse og deres anvendelse i farmasoytiske preparater | |
IL131478A0 (en) | Methods for treatment of scar tissue | |
GB0102145D0 (en) | Substances | |
EA200000909A1 (ru) | ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА | |
ATE243515T1 (de) | Verwendung der angiotensin ii-antagonisten losartan und exp-3174 zur behandlung von symptomatisches herzversagen | |
DK0970106T3 (da) | uPAR-imiterende peptider | |
FR2786699B1 (fr) | Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles | |
TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1137436 Country of ref document: EP |